DocWire News Editors

DocwireNews

According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic leukemia (CLL) experienced a sustained benefit with acalabrutinib monotherapy compared with standard-of-care regimens. These findings were presented at the 2021 American Society of Hematology Annual Meeting.
In the primary analysis of the phase III randomized ASCEND study, at a median follow-up of 16.1 months, treatment with acalabrutinib led to prolonged progression-free survival (PFS) compared with idelalisib plus rituximab (ldR) or bendamustine plus rituximab (BR), with a favorable safety profile.
Patients were randomized 1:1 to either oral acalabrutinib 100 mg twice daily (n = 155) or investigators’ choice of eight cycles of IdR (n = 119) or six cycles of BR (n = 36). Treatment continued until disease progression or unacceptable toxicity. Patients who progressed on IdR or BR were allowed to crossover to acalabrutinib monotherapy.
At a median follow-up of 36.0 months for the acalabrutinib arm and 35.2 months for the IdR/BR arm, the overall response rates were 83% and 85%, respectively. Median PFS had not been reached in the acalabrutinib group, compared with 16.8 months in the IdR/BR arm (hazard ratio [HR] = 0.29, 95% confidence interval [CI] 0.21-0.41; p &lt; 0.0001). The three-year PFS rates were 63% versus 21% in favor of acalabrutinib. The researchers noted that this PFS benefit was sustained regardless of IdR or BR treatment (all p &lt; 0.0001).
Additionally, high-risk subgroups also experienced a PFS benefit with acalabrutinib treatment. Three-year PFS rates were 66% and 5% for acalabrutinib and IdR/BR, respectively, among patients with del17p mutations (HR = 0.13; p &lt; 0.0001), and 61% and 17%, respectively, in patients with unmutated IGHV (HR = 0.3; p &lt; 0.0001). Median OS was not reached in either treatment arm. The three-year OS rates were 80% for acalabrutinib and 73% for standard of care.
The most common adverse events (AEs) with acalabrutinib, occurring in ≥20% of patients, were headache, neutropenia, diarrhea, and upper respiratory tract infection. Similarly, the most common AEs with IdR were diarrhea and neutropenia; for BR they were neutropenia, fatigue, infusion-related reaction, and nausea. Thirty-eight percent of acalabrutinib-treated patients reported serious AEs, compared with 63% of IdR patients and 26% of BR patients. The most common serious AEs were pneumonia (acalabrutinib 8%; IdR 9%; BR 3%), pyrexia (2%; 7%; 3%), and diarrhea (1%; 15%; 0%). AE-related discontinuation occurred in 21% of acalabrutinib-treated patients, compared with 65% and 17% for IdR- and BR-treated, respectively. The authors also noted the following events of clinical interest: all-grade atrial fibrillation/flutter (acalabrutinib, 6%; IdR/BR, 3%), all-grade hypertension (7%; 4%), all-grade major hemorrhage (3%; 3%), grade ≥3 infections (25%; 27%), and all-grade secondary malignancies (7%; 3%).
The authors noted that the tolerability profile of acalabrutinib in this study was in line with the primary analysis, and no new safety findings were identified with longer-term follow-up.

According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic leukemia (CLL) experienced a sustained benefit with acalabrutinib monotherapy compared with standard-of-care regimens. These findings were presented at the 2021 American Society of Hematology Annual Meeting.In the primary analysis of the phase III randomized ASCEND study, at a median follow-up of 16.1 months, treatment with acalabrutinib led to prolonged progression-free survival (PFS) compared with idelalisib plus rituximab (ldR) or bendamustine plus rituximab (BR), with a favorable safety profile.Patients were randomized 1:1 to either oral acalabrutinib 100 mg twice daily (n = 155) or investigators’ choice of eight cycles of IdR (n = 119) or six cycles of BR (n = 36). Treatment continued until disease progression or unacceptable toxicity. Patients who progressed on IdR or BR were allowed to crossover to acalabrutinib monotherapy.At a median follow-up of 36.0 months for the acalabrutinib arm and 35.2 months for the IdR/BR arm, the overall response rates were 83% and 85%, respectively. Median PFS had not been reached in the acalabrutinib group, compared with 16.8 months in the IdR/BR arm (hazard ratio [HR] = 0.29, 95% confidence interval [CI] 0.21-0.41; p &lt; 0.0001). The three-year PFS rates were 63% versus 21% in favor of acalabrutinib. The researchers noted that this PFS benefit was sustained regardless of IdR or BR treatment (all p &lt; 0.0001).Additionally, high-risk subgroups also experienced a PFS benefit with acalabrutinib treatment. Three-year PFS rates were 66% and 5% for acalabrutinib and IdR/BR, respectively, among patients with del17p mutations (HR = 0.13; p &lt; 0.0001), and 61% and 17%, respectively, in patients with unmutated IGHV (HR = 0.3; p &lt; 0.0001). Median OS was not reached in either treatment arm. The three-year OS rates were 80% for acalabrutinib and 73% for standard of care.The most common adverse events (AEs) with acalabrutinib, occurring in ≥20% of patients, were headache, neutropenia, diarrhea, and upper respiratory tract infection. Similarly, the most common AEs with IdR were diarrhea and neutropenia; for BR they were neutropenia, fatigue, infusion-related reaction, and nausea. Thirty-eight percent of acalabrutinib-treated patients reported serious AEs, compared with 63% of IdR patients and 26% of BR patients. The most common serious AEs were pneumonia (acalabrutinib 8%; IdR 9%; BR 3%), pyrexia (2%; 7%; 3%), and diarrhea (1%; 15%; 0%). AE-related discontinuation occurred in 21% of acalabrutinib-treated patients, compared with 65% and 17% for IdR- and BR-treated, respectively. The authors also noted the following events of clinical interest: all-grade atrial fibrillation/flutter (acalabrutinib, 6%; IdR/BR, 3%), all-grade hypertension (7%; 4%), all-grade major hemorrhage (3%; 3%), grade ≥3 infections (25%; 27%), and all-grade secondary malignancies (7%; 3%).The authors noted that the tolerability profile of acalabrutinib in this study was in line with the primary analysis, and no new safety findings were identified with longer-term follow-up.

Leslie Feldman

New Discovery Reveals How the Body May Help Defeat Hepatitis B

Hepatitis

How Hepatitis B Makes the Liver More Vulnerable to Cancer — And What We Can Do About It

New AI-Driven Tool Flags Children at Risk for Asthma

Asthma

Latest News

Acalabrutinib Associated With High PFS Benefit in Relapsed/Refractory CLL

ASH Annual Meeting and Exposition 2021

According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic leukemia (CLL) experienced a sustained benefit with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe